Blood Cancer Therapy Successful in 75% of Trial Patients
New data from an ongoing Phase 1/2 clinical trial has revealed an experimental immunotherapy led to successful response rates in 73% of patients suffering from multiple myeloma, a deadly form of blood cancer. Based on this promising data, an application to the US Food and Drug Administration (FDA) has been filed to bring the drug to market.
The technology has been in development for decades but it has only been in the last few years that bispecific antibodies have finally reached clinical uses. There are currently three FDA-approved bispecfiic antibody therapies on the market (primarily targeting cancers), and more than 100 prospective antibodies in clinical trials (aimed at everything from Alzheimer's to diabetes).
You must be logged in to view this content.
Recent Comments